Background: To identify the risk factors for bronchiectasis patients with active pulmonary tuberculosis (APTB) and to develop a predictive nomogram model for estimating the risk of APTB in bronchiectasis patients.
Methods: A retrospective cohort study was conducted on 16,750 bronchiectasis patients hospitalized at the Affiliated Hospital of Guangdong Medical University and the Second Affiliated Hospital of Guangdong Medical University between January 2019 and December 2023. The 390 patients with APTB were classified as the case group, while 818 patients were randomly sampled by computer at a 1:20 ratio from the 16,360 patients with other infections to serve as the control group. Relevant indicators potentially leading to APTB in bronchiectasis patients were collected. Patients were categorized into APTB and inactive pulmonary tuberculosis (IPTB) groups based on the presence of tuberculosis. The general characteristics of both groups were compared. Variables were screened using the least absolute shrinkage and selection operator (LASSO) analysis, followed by multivariate logistic regression analysis. A nomogram model was established based on the analysis results. The model's predictive performance was evaluated using calibration curves, C-index, and ROC curves, and internal validation was performed using the bootstrap method.
Results: LASSO analysis identified 28 potential risk factors. Multivariate analysis showed that age, gender, TC, ALB, MCV, FIB, PDW, LYM, hemoptysis, and hypertension are independent risk factors for bronchiectasis patients with APTB ( < 0.05). The nomogram demonstrated strong calibration and discrimination, with a C-index of 0.745 (95% CI: 0.715-0.775) and an AUC of 0.744 for the ROC curve. Internal validation using the bootstrap method produced a C-index of 0.738, further confirming the model's robustness.
Conclusion: The nomogram model, developed using common clinical serological characteristics, holds significant clinical value for assessing the risk of APTB in bronchiectasis patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581853 | PMC |
| http://dx.doi.org/10.3389/fmed.2024.1457048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Prevalence of bronchiectasis in patients with inborn errors of immunity].
Rev Alerg Mex
December 2024
Pediatra con subespecialidad en Alergia e Inmunología Clínica; jefe del servicio y profesor titular de la especialidad de Alergia e Inmunología Clínica, Unidad Médica de Alta Especialidad, Hospital de Especialidades, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco.
Objective: To establish the prevalence of bronchiectasis, correlate the IgG IV or SC immunoglobulin dose and serum IgG levels with the total Bhalla score and the severity of bronchiectasis and associate serum IgG levels with the development of pulmonary infectious processes in patients with diagnosis of innate errors of immunity.
Methods: A descriptive, observational, cross-sectional study with patients over 18 years of age diagnosed with IBD. Clinical records and computed axial tomography were reviewed.
The Contribution of Carbapenem-Resistant Pseudomonas Aeruginosa Isolation to Clinical Outcomes in Hospitalized Patients with Exacerbations of Bronchiectasis: A Retrospective Cohort Study.
Lung
January 2025
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Background: The antibiotic resistance of Pseudomonas aeruginosa (PA) is increasingly severe in bronchiectasis patients. However, there is currently a lack of research on the clinical outcomes of carbapenem-resistant PA (CRPA) isolation in hospitalized exacerbations of bronchiectasis (HEB) patients. We investigated the incidence, risk factors, and clinical outcomes of PA and CRPA isolation in HEB patients.
View Article and Find Full Text PDFEosinopenia in bronchiectasis: A novel biomarker for morbidity and mortality.
Chron Respir Dis
January 2025
Pulmonary Institute, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.
Background: The paradigm of bronchiectasis is shifting away from its exclusive characterization as a neutrophilic condition. Patients with bronchiectasis and high eosinophil levels have been found to have a specific phenotype, but the clinical effect of eosinopenia remains unclear.
Method: A retrospective, single-center, observational study was conducted at a tertiary medical center.
Common Variable Immunodeficiency Associated With Noninfectious Pulmonary Complications and Its Treatment: Beyond Immunoglobulin Therapy.
Pulm Circ
January 2025
Division of Pulmonary Medicine, Henry Ford Hospital Detroit Michigan USA.
Common variable immunodeficiency (CVID) is a type of primary immunodeficiency that presents as a heterogenous disorder characterized by hypogammaglobinemia, poor response to vaccines, recurrent sinopulmonary infections, and can have noninfectious systemic manifestations. We performed a single-center, retrospective, observational study of five patients with noninfectious complications of CVID. All patients had CVID as defined by the European Society of Immunodeficiencies criteria and had received intravenous immunoglobulin therapy.
View Article and Find Full Text PDFA multirange paper-based analytical device for identifying low, moderate, and high P. aeruginosa bacterial loads in sputum samples.
Biosens Bioelectron
December 2024
Multidisciplinary Sepsis Group, Hospital Universitario Son Espases, Health Research Institute of Balearic Islands (IdISBa), Palma de Mallorca, Spain; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III Madrid, Spain. Electronic address:
In this article we introduce a multirange analytical device that extends the dynamic range of nanoparticle-based immunoassays thanks to a multisensor design. Multirange devices contain low- and high-range sensors in the same analytical platform. The low-range sensor defines the limit of detection and quantifies low concentrated analytes, whereas the high-range sensor defines the upper limit of the dynamic range.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!